514 Shares in HCA Healthcare, Inc. (NYSE:HCA) Bought by Hilltop Holdings Inc.

Hilltop Holdings Inc. purchased a new position in HCA Healthcare, Inc. (NYSE:HCA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 514 shares of the company’s stock, valued at approximately $209,000.

Several other hedge funds also recently made changes to their positions in HCA. Holocene Advisors LP boosted its holdings in shares of HCA Healthcare by 210.6% during the third quarter. Holocene Advisors LP now owns 306,796 shares of the company’s stock worth $124,691,000 after purchasing an additional 208,015 shares during the period. Centiva Capital LP increased its stake in shares of HCA Healthcare by 37.4% during the third quarter. Centiva Capital LP now owns 13,264 shares of the company’s stock valued at $5,391,000 after buying an additional 3,612 shares during the period. Edgestream Partners L.P. purchased a new position in HCA Healthcare during the 3rd quarter valued at $8,183,000. Caisse DE Depot ET Placement DU Quebec increased its position in shares of HCA Healthcare by 53.5% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 304,819 shares of the company’s stock valued at $123,888,000 after buying an additional 106,246 shares during the period. Finally, Rockefeller Capital Management L.P. grew its holdings in shares of HCA Healthcare by 1.9% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 23,090 shares of the company’s stock worth $9,380,000 after acquiring an additional 440 shares during the period. 62.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HCA has been the subject of a number of research reports. Royal Bank of Canada increased their price objective on HCA Healthcare from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Friday, August 23rd. Wolfe Research raised shares of HCA Healthcare to a “strong-buy” rating in a research report on Thursday, August 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $392.00 target price on shares of HCA Healthcare in a report on Tuesday, October 1st. Oppenheimer lifted their price objective on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. Finally, Barclays reduced their price target on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $380.29.

HCA Healthcare Trading Down 0.1 %

HCA Healthcare stock opened at $319.75 on Monday. The firm has a market capitalization of $80.99 billion, a price-to-earnings ratio of 14.36, a P/E/G ratio of 1.25 and a beta of 1.63. HCA Healthcare, Inc. has a 12-month low of $252.85 and a 12-month high of $417.14. The firm has a 50 day moving average of $363.85 and a 200 day moving average of $358.89. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Friday, December 13th will be paid a $0.66 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.83%. HCA Healthcare’s payout ratio is presently 11.85%.

Insider Activity

In other news, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the transaction, the senior vice president now owns 52,702 shares in the company, valued at $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael S. Cuffe sold 8,358 shares of HCA Healthcare stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the sale, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 21.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,155 shares of company stock worth $5,608,990 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.